CytomX advances colorectal cancer pipeline as Varseta-M heads toward registrational trial
CytomX Therapeutics (NASDAQ:CTMX) reported its full-year 2025 financial results and a strategic business update on March 16, 2026, highlighting the continued evolution of its Probody® platform.










